BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17523057)

  • 1. Metabolism and excretion of CP-122,721, a non-peptide antagonist of the neurokinin NK1 receptor, in dogs: identification of the novel cleaved product 5-trifluoromethoxy salicylic acid in plasma.
    Kamel A; Du Y; Colizza K; Prakash C
    Xenobiotica; 2007 May; 37(5):559-78. PubMed ID: 17523057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
    Colizza K; Awad M; Kamel A
    Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism, pharmacokinetics and excretion of a potent tachykinin NK1 receptor antagonist (CP-122,721) in rat: characterization of a novel oxidative pathway.
    Kamel A; Davis J; Potchoiba MJ; Prakash C
    Xenobiotica; 2006; 36(2-3):235-58. PubMed ID: 16702114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C; Cui D
    Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs.
    Prakash C; Cui D; Potchoiba MJ; Butler T
    Drug Metab Dispos; 2007 Aug; 35(8):1350-64. PubMed ID: 17496205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
    Prakash C; Soliman V
    Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excretion and biotransformation of cisapride in dogs and humans after oral administration.
    Meuldermans W; Van Peer A; Hendrickx J; Lauwers W; Swysen E; Bockx M; Woestenborghs R; Heykants J
    Drug Metab Dispos; 1988; 16(3):403-9. PubMed ID: 2900732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excretion, metabolism, and pharmacokinetics of CP-945,598, a selective cannabinoid receptor antagonist, in rats, mice, and dogs.
    Miao Z; Scott DO; Griffith DA; Day R; Prakash C
    Drug Metab Dispos; 2011 Dec; 39(12):2191-208. PubMed ID: 21875952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excretion and biotransformation of ketanserin after oral and intravenous administration in rats and dogs.
    Meuldermans W; Hendrickx J; Lauwers W; Swysen E; Hurkmans R; Knaeps F; Woestenborghs R; Heykants J
    Drug Metab Dispos; 1984; 12(6):772-81. PubMed ID: 6150829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
    Prakash C; O'Donnell J; Khojasteh-Bakht SC
    Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor.
    Obach RS; Margolis JM; Logman MJ
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):336-49. PubMed ID: 17965517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excretion and biotransformation of cisapride in rats after oral administration.
    Meuldermans W; Hendrickx J; Lauwers W; Hurkmans R; Mostmans E; Swysen E; Bracke J; Knaeps A; Heykants J
    Drug Metab Dispos; 1988; 16(3):410-9. PubMed ID: 2900733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats, and dogs.
    Miraglia L; Pagliarusco S; Bordini E; Martinucci S; Pellegatti M
    Drug Metab Dispos; 2010 Oct; 38(10):1876-91. PubMed ID: 20622044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
    Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
    Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways.
    Dalvie DK; Khosla NB; Navetta KA; Brighty KE
    Drug Metab Dispos; 1996 Nov; 24(11):1231-40. PubMed ID: 8937858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excretion and metabolism of lorcainide in rats, dogs and man.
    Meuldermans W; Hurkmans R; Swysen E; Hendrickx J; Thijssen J; Lauwers W; Heykants J
    Eur J Drug Metab Pharmacokinet; 1983; 8(4):335-49. PubMed ID: 6673971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats.
    Johnson KA; Prakash C
    Drug Metab Dispos; 2005 Aug; 33(8):1191-201. PubMed ID: 15886349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man.
    Meuldermans W; Hurkmans R; Swysen E; Hendrickx J; Michiels M; Lauwers W; Heykants J
    Eur J Drug Metab Pharmacokinet; 1981; 6(1):49-60. PubMed ID: 6788556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excretion, metabolism, and pharmacokinetics of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide, a selective cannabinoid receptor antagonist, in healthy male volunteers.
    Miao Z; Sun H; Liras J; Prakash C
    Drug Metab Dispos; 2012 Mar; 40(3):568-78. PubMed ID: 22187487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.